COEP vs. NKGN, OKYO, ACHL, QNCX, CYTH, BCLI, SRZN, ESLA, INKT, and PLUR
Should you be buying Coeptis Therapeutics stock or one of its competitors? The main competitors of Coeptis Therapeutics include NKGen Biotech (NKGN), OKYO Pharma (OKYO), Achilles Therapeutics (ACHL), Quince Therapeutics (QNCX), Cyclo Therapeutics (CYTH), Brainstorm Cell Therapeutics (BCLI), Surrozen (SRZN), Estrella Immunopharma (ESLA), MiNK Therapeutics (INKT), and Pluri (PLUR). These companies are all part of the "biological products, except diagnostic" industry.
NKGen Biotech (NYSE:NKGN) and Coeptis Therapeutics (NASDAQ:COEP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.
Coeptis Therapeutics' return on equity of 0.00% beat NKGen Biotech's return on equity.
NKGen Biotech has a beta of 0.62, meaning that its share price is 38% less volatile than the S&P 500. Comparatively, Coeptis Therapeutics has a beta of -0.92, meaning that its share price is 192% less volatile than the S&P 500.
In the previous week, Coeptis Therapeutics had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 3 mentions for Coeptis Therapeutics and 1 mentions for NKGen Biotech. Coeptis Therapeutics' average media sentiment score of 1.38 beat NKGen Biotech's score of 0.96 indicating that NKGen Biotech is being referred to more favorably in the media.
Coeptis Therapeutics received 5 more outperform votes than NKGen Biotech when rated by MarketBeat users.
Coeptis Therapeutics has a consensus price target of $3.00, indicating a potential upside of 1,009.47%. Given NKGen Biotech's higher probable upside, analysts plainly believe Coeptis Therapeutics is more favorable than NKGen Biotech.
76.2% of NKGen Biotech shares are owned by institutional investors. Comparatively, 13.9% of Coeptis Therapeutics shares are owned by institutional investors. 20.0% of NKGen Biotech shares are owned by company insiders. Comparatively, 21.5% of Coeptis Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Coeptis Therapeutics beats NKGen Biotech on 7 of the 12 factors compared between the two stocks.
Get Coeptis Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for COEP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COEP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Coeptis Therapeutics Competitors List
Related Companies and Tools
